sln124
Nucleic acidexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 20, 2019 (NCT04176653)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transmembrane protease serine 6RNAI INHIBITOR
TMPRSS6 rnai inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05499013 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2022 | Silence Therapeutics GmbH |
| NCT04718844 | Phase 1 | Apr 14, 2021 | Silence Therapeutics GmbH |
| NCT04559971 | Early Phase 1 (Phase 1) | Sep 3, 2020 | Silence Therapeutics GmbH |
| NCT04176653 | Phase 1 | Aug 20, 2019 | Silence Therapeutics GmbH |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Silence Therapeutics GmbH | For profit | 4 | 4 | 2 | 2019 |
1 organizations
Page 1 / 1